PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8748629-1	1995	We evaluated the efficacy, safety and tolerability of a new dopamine D-2 receptor agonist, pramipexole [(S)-2-amino-4,5,6,7-tetrahydro-6-propylamino-benzathiazol-dihydro chloride], as adjunctive therapy in patients with advanced Parkinson"s disease (PD).	Pramipexole	91-102	dopamine receptor D2	Homo sapiens	60-81	
19396436-0	2009	Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson"s disease patients.	Pramipexole	64-75	dopamine receptor D2	Homo sapiens	19-23	
19396436-1	2009	OBJECTIVE: To evaluate the impact of the DRD2 TaqIA and DRD3 Ser9Gly polymorphisms on the efficacy of pramipexole in treating patients with Parkinson"s disease (PD).	Pramipexole	102-113	dopamine receptor D2	Homo sapiens	41-45	
17161393-3	2007	Pramipexole, a dopamine D2/D3 receptor agonist used clinically in the treatment of Parkinson disease, did not affect glutamate-induced calcium influx but blocked dopaminergic neuronal death induced by glutamate.	Pramipexole	0-11	dopamine receptor D2	Homo sapiens	15-38	
10812530-1	2000	Pramipexole, a dopamine D2 receptor agonist, was tested in 174 patients with major depression, with or without melancholia and without psychotic features.	Pramipexole	0-11	dopamine receptor D2	Homo sapiens	15-35	
10201413-1	1999	OBJECTIVES: Pramipexole, a non-ergot dopamine D2/D3 receptor agonist, was investigated as an add on drug in advanced parkinsonian patients with motor fluctuations to assess efficacy, safety, and tolerance.	Pramipexole	12-23	dopamine receptor D2	Homo sapiens	37-60	
8665547-1	1995	We evaluated the efficacy, safety, tolerability, and pharmacokinetics of pramipexole, a novel dopamine D2 receptor agonist, in early Parkinson"s disease (PD).	Pramipexole	73-84	dopamine receptor D2	Homo sapiens	94-114	
21408026-1	2011	The purpose of this study was to determine the binding sites of pramipexole in extrastriatal dopaminergic regions because its antidepressive effects have been speculated to occur by activating the dopamine D(2) receptor subfamily in extrastriatal areas.	Pramipexole	64-75	dopamine receptor D2	Homo sapiens	197-219	
12737528-3	2003	Recently, bromocriptine, pramipexole and several other agonists of the dopamine D2-receptor subfamily (including D2, D3 and D4-subtypes) have been shown to have neuroprotective effects in parkinsonian models in vitro and in vivo.	Pramipexole	25-36	dopamine receptor D2	Homo sapiens	71-91	
11054154-7	2000	Pramipexole is a full dopamine agonist with high selectivity for the D2 dopamine receptor family.	Pramipexole	0-11	dopamine receptor D2	Homo sapiens	69-89	
34810175-3	2022	Previous small randomised controlled trials suggested that pramipexole, a dopamine D2/3 receptor agonist, may be effective for treating patients with unipolar and bipolar depression as it is known to influence motivational drive and reward processing.	Pramipexole	59-70	dopamine receptor D2	Homo sapiens	74-96	
34451897-1	2021	Treatment with the dopamine D2/D3 receptor agonist pramipexole has demonstrated promising clinical effects in patients with depression.	Pramipexole	51-62	dopamine receptor D2	Homo sapiens	19-42	
31324936-2	2019	OBJECTIVES: This study used computational modelling to characterise the reinforcement learning processes underlying patterns of PRL behaviour observed in SUD and OCD and to show how the dopamine D2/3 receptor agonist pramipexole and the D2/3 antagonist amisulpride affected these responses.	Pramipexole	217-228	dopamine receptor D2	Homo sapiens	186-208	
35605609-0	2022	Enhanced taste recognition following subacute treatment with the dopamine D2/D3 receptor agonist pramipexole in healthy volunteers.	Pramipexole	97-108	dopamine receptor D2	Homo sapiens	65-88	
33264473-8	2021	The DRD2 agonist, pramipexole, administered systemically caused colorectal propulsion that was prevented when the pelvic nerves were cut.	Pramipexole	18-29	dopamine receptor D2	Homo sapiens	4-8	
31235613-1	2019	A dopamine D2 receptor agonist, pramipexole, has been found to elicit neuroprotection in patients with Parkinson"s disease and restless leg syndrome.	Pramipexole	32-43	dopamine receptor D2	Homo sapiens	2-22